Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2029-01-30
Target enrollment:
Participant gender:
Summary
The object of this trial is to test whether ivonescimab is superior to standard chemotherapy (FOLFOX regimen) for the treatment of patients with advanced biliary tract cancer after failure of a first line of chemotherapy. It is only open to patients who participated in the SAFIR-ABC10 trial (NCT05615818) but did not receive experimental treatment.
Eligible patients will be randomised (2:1) to receive either ivonescimab or FOLFOX. Treatment will be continued until disease progression, or a maximum of 34 cycles of ivonescimab (experimental arm), whichever occurs first.
Phase:
PHASE2
Details
Lead Sponsor:
UNICANCER
Collaborators:
Belgian Group of Digestive Oncology Cancer Research UK & UCL Cancer Trials Centre Summit Therapeutics